Neurology & Brain Disorders Clinical Trials Update: Week 44, 2026

Published October 30, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)

This Phase 4 study looks at the use of nusinersen injections in children under the age of three who have spinal muscular atrophy and were previously treated with gene therapy. The goal is to see if nusinersen can further improve muscle movement and motor skills in these children who still face difficulties despite prior treatment. The study involves up to 14 visits over about two years and is taking place in several countries, offering a deeper understanding of how to best support young patients with this condition.

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

This Phase 3 trial tested the drug erenumab to prevent chronic migraine in children and adolescents. With 284 participants worldwide, the study has now completed and results are available. If erenumab proves effective, it could provide a new way to reduce the frequency of migraine days in young patients, potentially with fewer side effects than current treatments, improving quality of life for children facing frequent migraines.

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

This Phase 2 study is exploring a non-drug treatment using low-level laser light called transcranial photobiomodulation. It targets people aged 65 to 85 with mild cognitive impairment or early Alzheimer's disease. The treatment lasts eight weeks and aims to improve thinking and memory skills without medication. Nearly 200 participants took part across multiple U.S. sites, and results are eagerly awaited to see if this gentle approach can offer a new option for brain health.

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

This Phase 2 trial is studying the safety and effects of the intravenous drug efgartigimod in children and adolescents with generalized myasthenia gravis, a condition that causes muscle weakness due to immune system problems. The study includes about 15 participants aged 2 to under 18 and is active but not recruiting new patients. If successful, this treatment might improve muscle strength and daily functioning by targeting the immune cause of the disease.

A Study of NTRX-07 in Participants With Alzheimer's Disease

This Phase 2 study is testing a new drug called NTRX-07 in people with mild cognitive impairment or mild to moderate Alzheimer's disease. It focuses on evaluating the safety of the drug and how it behaves in the body. With 48 participants across several countries, the study aims to find out if NTRX-07 can slow down the progression of Alzheimer's, potentially offering another option for managing this challenging condition.

Neurology and brain disorder research continues to explore promising new treatments for conditions affecting muscle strength, migraine, and memory. Advances this week range from improving care for young children with spinal muscular atrophy to investigating non-drug options for Alzheimer's disease. These ongoing studies bring hope for better management and quality of life for patients and families facing neurological challenges.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.